Market Research Logo

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2015

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2015’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
Therapeutics Development
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals, Inc.
Angion Biomedica Corp.
Atox Bio Inc.
Avaxia Biologics, Inc.
Bolder Biotechnology, Inc.
Caladrius Biosciences, Inc.
Cantex Pharmaceuticals, Inc.
Cellerant Therapeutics, Inc.
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Gamida Cell Ltd.
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
Priaxon AG
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RestorGenex Corporation
RxBio, Inc.
Soligenix, Inc.
Stemedica Cell Technologies, Inc.
Terapio Corporation
Tonix Pharmaceuticals Holding Corp.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
517-PXN - Drug Profile
AB-103 - Drug Profile
ABC-294640 - Drug Profile
AEOL-10150 - Drug Profile
AEOL-10171 - Drug Profile
AVX-470 - Drug Profile
BB-3 - Drug Profile
BBT-007 - Drug Profile
BBT-015 - Drug Profile
BBT-018 - Drug Profile
BBT-045 - Drug Profile
BBT-059 - Drug Profile
BCN-057 - Drug Profile
BIO-300 - Drug Profile
BPC-2 - Drug Profile
C-2E2 - Drug Profile
C-2E5 - Drug Profile
CBLB-613 - Drug Profile
CLT-009 - Drug Profile
CX-02 - Drug Profile
EDL-2000 - Drug Profile
entolimod - Drug Profile
EWA-001 - Drug Profile
GC-003 - Drug Profile
GC-4403 - Drug Profile
GC-4419 - Drug Profile
HSJ-0017 - Drug Profile
JP4-039 - Drug Profile
LGM-2605 - Drug Profile
m2A2 - Drug Profile
Mesenchymal Stem Cells - Drug Profile
NMIL-121 - Drug Profile
ondansetron hydrochloride - Drug Profile
ondansetron hydrochloride CR - Drug Profile
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
pirfenidone - Drug Profile
pirfenidone - Drug Profile
PLXR-18 - Drug Profile
PrC-210 - Drug Profile
RDD-2007 - Drug Profile
recilisib sodium - Drug Profile
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
RES-529 - Drug Profile
RP-239X - Drug Profile
rusalatide acetate - Drug Profile
Rx-100 - Drug Profile
RX-101 - Drug Profile
SGX-201 - Drug Profile
SGX-202 - Drug Profile
Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile
Small Molecules for Radiation and Chemical Toxicity - Drug Profile
Small Molecules for Radiation Toxicity - Drug Profile
Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
ST-7 - Drug Profile
Stem Cell Therapy for Radiation Exposure - Drug Profile
SY-303A - Drug Profile
SY-513 - Drug Profile
Thrombosomes - Drug Profile
TPO-7630 - Drug Profile
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2015
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Avaxia Biologics, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Priaxon AG, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RestorGenex Corporation, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2015
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2015
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report